In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Gloria Pérez-Rodríguez *Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0009-0002-8039-6641 Lucía González-Pinto *Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0000-0002-8387-3784 Pablo Aja-MacayaServicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0000-0001-6296-5949 Carlos Molina-CáceresServicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0009-0000-6531-3102 Lucía Sánchez-PeñaServicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0009-0007-5696-5812 Tania Blanco-MartínServicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0009-0003-1636-6429 Antonio OliverCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-9327-1894 Germán BouServicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0000-0001-8837-0062 Jorge Arca-SuárezServicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain.ORCID 0000-0002-4248-503X Funding
Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas CB21/13/00055Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas CB21/13/00099Instituto de Salud Carlos III PI22/01212Instituto de Salud Carlos III PI24/00920Instituto de Salud Carlos III PI25/00116ISCIII PFIS program FI23/00074ISCII Juan Rodes Program JR21/00026ISCII Juan Rodes Program JR25/00031Xunta de Galicia IN606A 2024/022Xunta de Galicia IN606A 2025/020Xunta de Galicia IN607A 2024/09Xunta de Galicia IN607D 2024/08
6 · The paper itselfAbstract
The emergence of ceftazidime/avibactam resistance in an extended-spectrum β-lactamase (ESBL)-producing
Indexed as
Anti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCeftazidimePseudomonas aeruginosaDrug CombinationsDrug Resistance, Multiple, BacterialHumansIntegronsMicrobial Sensitivity TestsPlasmidsPseudomonas InfectionsThird Generation CephalosporinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-lactamase OXA-2beta-LactamasesCeftazidimeDrug CombinationsThird Generation CephalosporinsBELceftazidime/avibactamESBLevolutionmutational mechanismsOXAPseudomonas aeruginosaβ-lactamβ-lactamaseβ-lactamase inhibitorβ-lactam resistance
Identifiers
PMID42615933
PMCPMC13689465
What OpenQuestion holds
Textmetadata
Read underepoch 390